Wim Van Den Brink
Professor of Clinical Epidemiology in Addiction Care at the University of Amsterdam / Amsterdam UMC (emeritus professor)
Data updated
Research Footprint
Wim Van Den Brink appears in 6 tracked papers (2011–2024), most studied alongside Psilocybin, MDMA and Esketamine, across Anxiety Disorders, Depressive Disorders and Treatment-Resistant Depression (TRD).
Most-cited paper: Harm potential of magic mushroom use: A review (205 citations).
Frequent co-authors: Joost Breeksema, Robert Schoevers and Jeanine Kamphuis.
Background & Research
Wim van den Brink is a Dutch psychiatrist and addiction researcher associated with the University of Amsterdam and Amsterdam UMC. His work has focused on addiction epidemiology, treatment, and drug policy, including MDMA, cannabis, and other substance-related harms. He has also coauthored recent psychedelic-safety and psilocybin-related papers in clinical and policy contexts.
Key Impact
He is a leading Dutch addiction psychiatrist whose expertise in substance use, harm reduction, and drug policy appears in psychedelics- and MDMA-related safety and policy research.
Collaboration Network
7 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Wim Van Den Brink is associated with.
University of Amsterdam
The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.
View stakeholder →OPEN Foundation
Non-ProfitDutch nonprofit organizer in the psychedelic field, including stewardship of the ICPR conference series and related professional convenings.
View stakeholder →Clearmind Medicine
Public BiotechClearmind Medicine is an Israeli-American biotech developing CMND-100, a proprietary oral MEAI (5-methoxy-2-aminoindane) formulation for alcohol use disorder. First patient dosed in June 2025 in their multinational Phase 1/2a trial across Yale, Johns Hopkins, and Hadassah Medical Center. Positive first cohort top-line results reported November 2025.
View stakeholder →